Literature DB >> 1465449

Genomic structure of the human caldesmon gene.

K Hayashi1, H Yano, T Hashida, R Takeuchi, O Takeda, K Asada, E Takahashi, I Kato, K Sobue.   

Abstract

The high molecular weight caldesmon (h-CaD) is predominantly expressed in smooth muscles, whereas the low molecular weight caldesmon (l-CaD) is widely distributed in nonmuscle tissues and cells. The changes in CaD isoform expression are closely correlated with the phenotypic modulation of smooth muscle cells. During a search for isoform diversity of human CaDs, l-CaD cDNAs were cloned from HeLa S3 cells. HeLa l-CaD I is composed of 558 amino acids, whereas 26 amino acids (residues 202-227 for HeLa l-CaD I) are deleted in HeLa l-CaD II. The short amino-terminal sequence of HeLa l-CaDs is different from that of fibroblast (WI-38) l-CaD II and human aorta h-CaD. We have also identified WI-38 l-CaD I, which contains a 26-amino acid insertion relative to WI-38 l-CaD II. To reveal the molecular events of the expressional regulation of the CaD isoforms, the genomic structure of the human CaD gene was determined. The human CaD gene is composed of 14 exons and was mapped to a single locus, 7q33-q34. The 26-amino acid insertion is encoded in exon 4 and is specifically spliced in the mRNAs for both h-CaD and l-CaDs I. Exon 3 is the exon that encodes the central repeating domain specific to h-CaD (residues 208-436) together with the common domain in all CaD (residues 73-207 for h-CaD and WI-38 l-CaDs, and residues 68-201 for HeLa l-CaDs). The regulation of h- and l-CaD expression is thought to depend on selection of the two 5' splice sites within exon 3. Thus, the change in expression between l-CaD and h-CaD might be caused by this splicing pathway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1465449      PMCID: PMC50710          DOI: 10.1073/pnas.89.24.12122

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  R-banding and nonisotopic in situ hybridization: precise localization of the human type II collagen gene (COL2A1).

Authors:  E Takahashi; T Hori; P O'Connell; M Leppert; R White
Journal:  Hum Genet       Date:  1990-11       Impact factor: 4.132

Review 2.  Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems.

Authors:  K Sobue; J R Sellers
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

3.  Sequence of an avian non-muscle caldesmon.

Authors:  J Bryan; R Lee
Journal:  J Muscle Res Cell Motil       Date:  1991-08       Impact factor: 2.698

4.  Characterization of cDNA clones encoding a human fibroblast caldesmon isoform and analysis of caldesmon expression in normal and transformed cells.

Authors:  R E Novy; J L Lin; J J Lin
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

5.  Polymerase chain reaction (PCR) amplification with a single specific primer.

Authors:  M Kalman; E T Kalman; M Cashel
Journal:  Biochem Biophys Res Commun       Date:  1990-03-16       Impact factor: 3.575

6.  Purification and characterization of pre-mRNA splicing factor SF2 from HeLa cells.

Authors:  A R Krainer; G C Conway; D Kozak
Journal:  Genes Dev       Date:  1990-07       Impact factor: 11.361

7.  The essential pre-mRNA splicing factor SF2 influences 5' splice site selection by activating proximal sites.

Authors:  A R Krainer; G C Conway; D Kozak
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

8.  Regulation of sexual differentiation in D. melanogaster via alternative splicing of RNA from the transformer gene.

Authors:  R T Boggs; P Gregor; S Idriss; J M Belote; M McKeown
Journal:  Cell       Date:  1987-08-28       Impact factor: 41.582

9.  Genome walking by single-specific-primer polymerase chain reaction: SSP-PCR.

Authors:  V Shyamala; G F Ames
Journal:  Gene       Date:  1989-12-07       Impact factor: 3.688

10.  Localization of the calmodulin- and the actin-binding sites of caldesmon.

Authors:  C L Wang; L W Wang; S A Xu; R C Lu; V Saavedra-Alanis; J Bryan
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

View more
  29 in total

1.  A note on the caldesmon sequence.

Authors:  H Guo; J Bryan; C L Wang
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

2.  SR proteins are sufficient for exon bridging across an intron.

Authors:  J M Stark; D P Bazett-Jones; M Herfort; M B Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

3.  A short sequence within two purine-rich enhancers determines 5' splice site specificity.

Authors:  L L Elrick; M B Humphrey; T A Cooper; S M Berget
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

4.  Smooth muscle alternative splicing induced in fibroblasts by heterologous expression of a regulatory gene.

Authors:  G C Roberts; C Gooding; C W Smith
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

Review 5.  Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation.

Authors:  K Sobue; K Hayashi; W Nishida
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

6.  Stretch affects phenotype and proliferation of vascular smooth muscle cells.

Authors:  K G Birukov; V P Shirinsky; O V Stepanova; V A Tkachuk; A W Hahn; T J Resink; V N Smirnov
Journal:  Mol Cell Biochem       Date:  1995-03-23       Impact factor: 3.396

Review 7.  Diversification of caldesmon-linked actin cytoskeleton in cell motility.

Authors:  Taira Mayanagi; Kenji Sobue
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

8.  Polypyrimidine tract binding protein functions as a repressor to regulate alternative splicing of alpha-actinin mutally exclusive exons.

Authors:  J Southby; C Gooding; C W Smith
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

9.  cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon.

Authors:  Raphaela Schwappacher; Hema Rangaswami; Jacqueline Su-Yuo; Aaron Hassad; Ryan Spitler; Darren E Casteel
Journal:  J Cell Sci       Date:  2013-02-15       Impact factor: 5.285

Review 10.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.